Figure 1.
Patient 3. Forehead basal cell carcinoma lesions before everolimus treatment (a) and after six months of everolimus 3 mg daily (b).
Patient 3. Forehead basal cell carcinoma lesions before everolimus treatment (a) and after six months of everolimus 3 mg daily (b).